On October 16, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, reported that new preclinical data from its ATR inhibitor program will be presented in a poster session at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), held October 22-26 at the Hynes Convention Center Boston, Massachusetts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DNA damage repair (DDR) enzymes, including Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR), are crucial for maintaining stability in cells. Inhibition of DDR enzymes has proven to be a compelling therapeutic option for numerous cancer indications. However, they lack the ability to effectively penetrate through the blood-brain barrier into the central nervous system (CNS), making them suboptimal for the treatment of brain tumors and metastases.
Rakovina’s presentation will highlight the Company’s ATR inhibitor program developed in collaboration with Variational AI and their Enki generative AI platform. This platform was used to create a shortlist of compounds with properties to selectively target ATR. The most promising molecules from this list were synthesized and characterized in vitro and in vivo. Data on the potency, selectivity, CNS penetrance and metabolic stability of select inhibitors will be presented and members of the team will be available for discussion with potential collaborators.
"The data to be presented at AACR (Free AACR Whitepaper)-NCI-EORTC reflects the continued progress of our AI-driven drug discovery pipeline and the importance of our collaboration with Variational AI," said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. "Our ATR inhibitor drug candidates show strong efficacy and blood-brain barrier permeability, a critical unmet need in current cancer therapies."
Presentation Details:
Title: Novel ATR inhibitors with CNS penetrance developed by artificial intelligence
Presentation Date: Poster session C, Saturday, October 25, 12:30 – 4 pm ET
(Press release, Rakovina Therapeutics, OCT 16, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-to-present-new-data-highlighting-novel-atr-inhibitor-with-cns-penetration-at-the-aacr-nci-eortc-international-conference [SID1234656707])